(Q37213526)

English

A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study (English)

1 reference

Europe PubMed Central

19 August 2017

object named as

Jane A Cauley

13

0 references

Caren M. Gundberg

12

object named as

Caren M Gundberg

1 reference

Europe PubMed Central

19 August 2017

author name string

Mara J Horwitz

1

1 reference

Europe PubMed Central

19 August 2017

Marilyn Augustine

2

1 reference

Europe PubMed Central

19 August 2017

Leila Khan

3

1 reference

Europe PubMed Central

19 August 2017

Emily Martin

4

1 reference

Europe PubMed Central

19 August 2017

Christine C Oakley

5

1 reference

Europe PubMed Central

19 August 2017

Raquel M Carneiro

6

1 reference

Europe PubMed Central

19 August 2017

Mary Beth Tedesco

7

1 reference

Europe PubMed Central

19 August 2017

Angela Laslavic

8

1 reference

Europe PubMed Central

19 August 2017

Susan M Sereika

9

1 reference

Europe PubMed Central

19 August 2017

Alessandro Bisello

10

1 reference

Europe PubMed Central

19 August 2017

Adolfo Garcia-Ocaña

11

1 reference

Europe PubMed Central

19 August 2017

Andrew F Stewart

14

1 reference

Europe PubMed Central

19 August 2017

publication date

1 November 2013

1 reference

Europe PubMed Central

19 August 2017

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

19 August 2017

28

1 reference

Europe PubMed Central

19 August 2017

11

1 reference

Europe PubMed Central

19 August 2017

2266-2276

1 reference

Europe PubMed Central

19 August 2017

Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

6 September 2017

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

14 September 2017

Parathyroid hormone-related protein-(1-36) is biologically active when administered subcutaneously to humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

28 September 2017

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

26 June 2018

Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

3 September 2018

Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

3 September 2018

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

3 September 2018

Candidate reference method for the quantification of circulating 25-hydroxyvitamin D3 by liquid chromatography-tandem mass spectrometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

3 September 2018

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

3 September 2018

Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

3 September 2018

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

3 September 2018

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3789852

3 September 2018

Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantification of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with 125I-labeled tracer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dissociation of bone formation from resorption during 2-week treatment with human parathyroid hormone-related peptide-(1-36) in humans: potential as an anabolic therapy for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in vitamin D metabolites during teriparatide treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of osteoanabolic therapy: a decade of experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23661240

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/JBMR.1978

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37213526&oldid=1694777952"